Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 44, Issue 5, 2007, Pages 557-561

  Ramos, Belén ^a   Núñez, Marina ^a   Martín Carbonero, Luz ^a   Sheldon, Julie ^a   Rios, Pilar ^a   Labarga, Pablo ^a   Romero, Miriam ^a   Barreiro, Pablo ^a   García Samaniego, Javier ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Hepatitis B; Hepatitis B virus genotypes; HIV; Lamivudine; Liver; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DELTA AGENT HEPATITIS; DRUG ABUSE; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SEXUAL INTERCOURSE; SUPERINFECTION; TREATMENT DURATION; VIREMIA; VIRUS GENOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENES, VIRAL; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION;

EID: 34247171652     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3180314b46     Document Type: Article

References (35)

1. Lee W. Hepatitis B virus infection. N Engl J Med. 1997;337:1733-1745.
2. Chu C, Lok A. Clinical significance of hepatitis B virus genotypes. Hepatology. 2002;35:1274-1276.
3. Mayerat C, Mantegani A, Frei P. Does hepatitis B virus HBV genotype influence the clinical outcome of HBV infection? J Viral Hepat. 1999;6:299-304.
4. Sanchez-Tapias J, Costa J, Mas A, et al. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in Western patients. Gastroenterology. 2002;123:1848-1856.
5. Hou J, Schilling R, Janssen H. Molecular characteristics of hepatitis B virus genotype A confer a higher response to interferon treatment. J Hepatol. 2001;34(Suppl 1):15.
6. Tsubota A, Arase Y, Ren F, et al. Genotype may correlate with liver carcinogenesis and tumor characteristics in cirrhotic patients infected with hepatitis B virus subtype adw. J Med Virol. 2001;65:257-265.
7. Perez-Olmeda M, Nuñez M, Garcia-Samaniego J, et al. Distribution of hepatitis B virus genotypes in HIV-infected patients with chronic hepatitis B: therapeutic implications. AIDS Res Hum Retroviruses. 2003;8:657-659.
8. Lacombe K, Massari V, Girard P, et al. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS. 2006;20:419-427.
9. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005;19:593-601.
10. Kao J, Chen D. Global control of hepatitis B virus. Lancet Infect Dis. 2002;2:395-403.
11. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV international panel. AIDS. 2005;19:221-240.
12. Puoti M, Airoldi M, Bruno R, et al. Hepatitis B virus coinfection in HIV-infected subjects. AIDS Rev. 2002;4:27-35.
13. Thio C, Seaberg E, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet. 2002;360:1921-1926.
14. Thio C, Sulkowski M, Thomas D. Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box. Clin Infect Dis. 2005;41:1035-1040.
15. Sandrin L, Fourquet B, Hasquenoph J, et al. Transient elastography: a new non-invasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705-1713.
16. Norder H, Couroucé A, Magnius L. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology. 1994;198:489-503.
17. Stuyver L, De Gendt S, Van Geyt C, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol. 2000;81:67-74.
18. Arauz-Ruiz P, Norder H, Robertson B, et al. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol. 2002;83:2059-2073.
19. Lindh M, Andersson A, Gusdal A. Genotypes and geographic origin of hepatitis B virus: large-scale analysis using a new genotyping method. J Infect Dis. 1997;175:1285-1293.
20. Rodriguez-Frias F, Buti M, Jardi R, et al. Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology. 1995;22:1641-1647.
21. Chu C, Keeffe E, Han S, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology. 2003;38:619-628.
22. Grandjacques C, Pradat P, Stuyvert L, et al. Rapid detection of genotypes and mutations in the basal core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol. 2000;33:430-439.
23. Hunt C, McGill J, Allen M, et al. Clinical relevance of hepatitis B viral mutations. Hepatology. 2000;31:1037-1044.
24. Kao J, Wu N, Chen P, et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol. 2000;33:998-1002.
25. Doong S, Tsai C, Schinazi R, et al. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA. 1991;88:8495-8499.
26. Coates J, Cammack N, Jenkinson H, et al. (-)-2′-deoxy-3′- thiacytidine is a potent, highly selective inhibitor of HIV type 1 and type 2 replication in vitro. Antimicrob Agents Chemother. 1992;36:733-739.
27. Stuyver L, Locarnini S, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology. 2001;33:751-757.
28. Matthews G, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS. 2006;20:863-870.
29. Cooley L, Ayres A, Bartholomeusz A, et al. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS. 2003;17:1649-1657.
30. Leung N, Lai C, Chang T, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001;33:1527-1532.
31. Torresi J, Earnest-Silveira L, Deliyannis G, et al. Reduced antigenicity of the HBV HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology. 2002;293:305-313.
32. Janssen H, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123-129.
33. Núñez M, Ramos B, Díaz-Pollán B, et al. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Res Hum Retroviruses. 2006;22:842-848.
34. Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther. 2004;9:679-693.
35. Osborn M, Lock A. Antiviral options for the treatment of chronic hepatitis B. Int J Antimicrob Agents. 2006;57:1030-1034.